No Cover Image

Journal article 1509 views

Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus

Jeffrey Stephens Orcid Logo, T Bodvarsdottir, K Wareham, Sarah Prior Orcid Logo, R Bracken, G Lowe, A Rumley, G Dunseath, Steve Luzio, C Deacon, J Holst, Steve Bain, Richard Bracken Orcid Logo, Gareth Dunseath Orcid Logo, Steve Luzio Orcid Logo

Diabetes Research and Clinical Practice, Volume: 94, Issue: 2, Pages: 199 - 206

Swansea University Authors: Jeffrey Stephens Orcid Logo, Sarah Prior Orcid Logo, Richard Bracken Orcid Logo, Gareth Dunseath Orcid Logo, Steve Luzio Orcid Logo

Full text not available from this repository: check for access using links below.

DOI (Published version): 10.1016/j.diabres.2011.07.014

Abstract

To examine the effects of glibenclamide and repaglinide on glucose stimulated insulin release, incretins, oxidative stress and cell adhesion molecules in patients with type 2 diabetes suboptimally treated with metformin.A randomized clinical trial was performed recruiting 27 subjects (HbA1c between...

Full description

Published in: Diabetes Research and Clinical Practice
Published: 2011
Online Access: http://www.sciencedirect.com/science/article/pii/S0168822711003640
URI: https://cronfa.swan.ac.uk/Record/cronfa10733
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2013-07-23T12:04:10Z
last_indexed 2018-02-09T04:39:47Z
id cronfa10733
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2014-12-05T15:05:08.5759284</datestamp><bib-version>v2</bib-version><id>10733</id><entry>2012-05-09</entry><title>Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus</title><swanseaauthors><author><sid>5219d126f97f8f884bdb622099bd41de</sid><ORCID>0000-0003-2228-086X</ORCID><firstname>Jeffrey</firstname><surname>Stephens</surname><name>Jeffrey Stephens</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>cdda101035997acfaa6fdf17097f52b2</sid><ORCID>0000-0001-8703-8092</ORCID><firstname>Sarah</firstname><surname>Prior</surname><name>Sarah Prior</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>f5da81cd18adfdedb2ccb845bddc12f7</sid><ORCID>0000-0002-6986-6449</ORCID><firstname>Richard</firstname><surname>Bracken</surname><name>Richard Bracken</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>fccbba9edcaee08a839a3c5cff8cbe19</sid><ORCID>0000-0001-6022-862X</ORCID><firstname>Gareth</firstname><surname>Dunseath</surname><name>Gareth Dunseath</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>01491e1cd582746a654fad9addf0de16</sid><ORCID>0000-0002-7206-6530</ORCID><firstname>Steve</firstname><surname>Luzio</surname><name>Steve Luzio</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2012-05-09</date><deptcode>BMS</deptcode><abstract>To examine the effects of glibenclamide and repaglinide on glucose stimulated insulin release, incretins, oxidative stress and cell adhesion molecules in patients with type 2 diabetes suboptimally treated with metformin.A randomized clinical trial was performed recruiting 27 subjects (HbA1c between 7.5 and 10.5%) free from cardiovascular and renal disease. Glucose, insulin, C-peptide, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), total antioxidant status, F2-isoprostane, interleukin-6 and cell adhesion molecules were measured during an oral glucose load at baseline and after eight weeks of treatment. The areas under the curve were analysed at 45, 60 and 120 min (AUC45, AUC60, AUC120).Significant improvements in glucose were observed with repaglinide (HBA1c: &#x2212;1.5%, fasting glucose: &#x2212;2.8 mmol/L, 2-h glucose: &#x2212;3.7 mmol/L, AUC120: &#x2212;18.9%) and glibenclamide (&#x2212;1.0%, &#x2212;2.2 mmol/L, &#x2212;2.5 mmol/L, &#x2212;17.5%). Repaglinide was also associated with an increase in the AUC60 and AUC120 for insulin (+56%, +61%) and C-peptide (+41%, +36%). GLP-1, GIP, IL-6, ICAM-1 and E-selectin levels did not change in either group. No association was observed between GLP-1, GIP-1 and plasma markers of oxidative stress.Repaglinide is associated with improved postprandial glycaemic control via insulin and C-peptide release. We observed no direct effects of glibenclamide or repaglinide on plasma levels of GLP-1 or GIP. We observed no associations of GLP-1 and GIP with plasma markers of oxidative stress.</abstract><type>Journal Article</type><journal>Diabetes Research and Clinical Practice</journal><volume>94</volume><journalNumber>2</journalNumber><paginationStart>199</paginationStart><paginationEnd>206</paginationEnd><publisher/><issnPrint/><issnElectronic/><keywords>Glibenclamide; Repaglinide; GLP-1; GIP; Insulin; Oxidative stress; Diabetes</keywords><publishedDay>31</publishedDay><publishedMonth>12</publishedMonth><publishedYear>2011</publishedYear><publishedDate>2011-12-31</publishedDate><doi>10.1016/j.diabres.2011.07.014</doi><url>http://www.sciencedirect.com/science/article/pii/S0168822711003640</url><notes></notes><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm/><lastEdited>2014-12-05T15:05:08.5759284</lastEdited><Created>2012-05-09T11:17:26.4348781</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Jeffrey</firstname><surname>Stephens</surname><orcid>0000-0003-2228-086X</orcid><order>1</order></author><author><firstname>T</firstname><surname>Bodvarsdottir</surname><order>2</order></author><author><firstname>K</firstname><surname>Wareham</surname><order>3</order></author><author><firstname>Sarah</firstname><surname>Prior</surname><orcid>0000-0001-8703-8092</orcid><order>4</order></author><author><firstname>R</firstname><surname>Bracken</surname><order>5</order></author><author><firstname>G</firstname><surname>Lowe</surname><order>6</order></author><author><firstname>A</firstname><surname>Rumley</surname><order>7</order></author><author><firstname>G</firstname><surname>Dunseath</surname><order>8</order></author><author><firstname>Steve</firstname><surname>Luzio</surname><order>9</order></author><author><firstname>C</firstname><surname>Deacon</surname><order>10</order></author><author><firstname>J</firstname><surname>Holst</surname><order>11</order></author><author><firstname>Steve</firstname><surname>Bain</surname><order>12</order></author><author><firstname>Richard</firstname><surname>Bracken</surname><orcid>0000-0002-6986-6449</orcid><order>13</order></author><author><firstname>Gareth</firstname><surname>Dunseath</surname><orcid>0000-0001-6022-862X</orcid><order>14</order></author><author><firstname>Steve</firstname><surname>Luzio</surname><orcid>0000-0002-7206-6530</orcid><order>15</order></author></authors><documents/><OutputDurs/></rfc1807>
spelling 2014-12-05T15:05:08.5759284 v2 10733 2012-05-09 Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus 5219d126f97f8f884bdb622099bd41de 0000-0003-2228-086X Jeffrey Stephens Jeffrey Stephens true false cdda101035997acfaa6fdf17097f52b2 0000-0001-8703-8092 Sarah Prior Sarah Prior true false f5da81cd18adfdedb2ccb845bddc12f7 0000-0002-6986-6449 Richard Bracken Richard Bracken true false fccbba9edcaee08a839a3c5cff8cbe19 0000-0001-6022-862X Gareth Dunseath Gareth Dunseath true false 01491e1cd582746a654fad9addf0de16 0000-0002-7206-6530 Steve Luzio Steve Luzio true false 2012-05-09 BMS To examine the effects of glibenclamide and repaglinide on glucose stimulated insulin release, incretins, oxidative stress and cell adhesion molecules in patients with type 2 diabetes suboptimally treated with metformin.A randomized clinical trial was performed recruiting 27 subjects (HbA1c between 7.5 and 10.5%) free from cardiovascular and renal disease. Glucose, insulin, C-peptide, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), total antioxidant status, F2-isoprostane, interleukin-6 and cell adhesion molecules were measured during an oral glucose load at baseline and after eight weeks of treatment. The areas under the curve were analysed at 45, 60 and 120 min (AUC45, AUC60, AUC120).Significant improvements in glucose were observed with repaglinide (HBA1c: −1.5%, fasting glucose: −2.8 mmol/L, 2-h glucose: −3.7 mmol/L, AUC120: −18.9%) and glibenclamide (−1.0%, −2.2 mmol/L, −2.5 mmol/L, −17.5%). Repaglinide was also associated with an increase in the AUC60 and AUC120 for insulin (+56%, +61%) and C-peptide (+41%, +36%). GLP-1, GIP, IL-6, ICAM-1 and E-selectin levels did not change in either group. No association was observed between GLP-1, GIP-1 and plasma markers of oxidative stress.Repaglinide is associated with improved postprandial glycaemic control via insulin and C-peptide release. We observed no direct effects of glibenclamide or repaglinide on plasma levels of GLP-1 or GIP. We observed no associations of GLP-1 and GIP with plasma markers of oxidative stress. Journal Article Diabetes Research and Clinical Practice 94 2 199 206 Glibenclamide; Repaglinide; GLP-1; GIP; Insulin; Oxidative stress; Diabetes 31 12 2011 2011-12-31 10.1016/j.diabres.2011.07.014 http://www.sciencedirect.com/science/article/pii/S0168822711003640 COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University 2014-12-05T15:05:08.5759284 2012-05-09T11:17:26.4348781 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Jeffrey Stephens 0000-0003-2228-086X 1 T Bodvarsdottir 2 K Wareham 3 Sarah Prior 0000-0001-8703-8092 4 R Bracken 5 G Lowe 6 A Rumley 7 G Dunseath 8 Steve Luzio 9 C Deacon 10 J Holst 11 Steve Bain 12 Richard Bracken 0000-0002-6986-6449 13 Gareth Dunseath 0000-0001-6022-862X 14 Steve Luzio 0000-0002-7206-6530 15
title Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus
spellingShingle Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus
Jeffrey Stephens
Sarah Prior
Richard Bracken
Gareth Dunseath
Steve Luzio
title_short Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus
title_full Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus
title_fullStr Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus
title_full_unstemmed Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus
title_sort Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus
author_id_str_mv 5219d126f97f8f884bdb622099bd41de
cdda101035997acfaa6fdf17097f52b2
f5da81cd18adfdedb2ccb845bddc12f7
fccbba9edcaee08a839a3c5cff8cbe19
01491e1cd582746a654fad9addf0de16
author_id_fullname_str_mv 5219d126f97f8f884bdb622099bd41de_***_Jeffrey Stephens
cdda101035997acfaa6fdf17097f52b2_***_Sarah Prior
f5da81cd18adfdedb2ccb845bddc12f7_***_Richard Bracken
fccbba9edcaee08a839a3c5cff8cbe19_***_Gareth Dunseath
01491e1cd582746a654fad9addf0de16_***_Steve Luzio
author Jeffrey Stephens
Sarah Prior
Richard Bracken
Gareth Dunseath
Steve Luzio
author2 Jeffrey Stephens
T Bodvarsdottir
K Wareham
Sarah Prior
R Bracken
G Lowe
A Rumley
G Dunseath
Steve Luzio
C Deacon
J Holst
Steve Bain
Richard Bracken
Gareth Dunseath
Steve Luzio
format Journal article
container_title Diabetes Research and Clinical Practice
container_volume 94
container_issue 2
container_start_page 199
publishDate 2011
institution Swansea University
doi_str_mv 10.1016/j.diabres.2011.07.014
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
url http://www.sciencedirect.com/science/article/pii/S0168822711003640
document_store_str 0
active_str 0
description To examine the effects of glibenclamide and repaglinide on glucose stimulated insulin release, incretins, oxidative stress and cell adhesion molecules in patients with type 2 diabetes suboptimally treated with metformin.A randomized clinical trial was performed recruiting 27 subjects (HbA1c between 7.5 and 10.5%) free from cardiovascular and renal disease. Glucose, insulin, C-peptide, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), total antioxidant status, F2-isoprostane, interleukin-6 and cell adhesion molecules were measured during an oral glucose load at baseline and after eight weeks of treatment. The areas under the curve were analysed at 45, 60 and 120 min (AUC45, AUC60, AUC120).Significant improvements in glucose were observed with repaglinide (HBA1c: −1.5%, fasting glucose: −2.8 mmol/L, 2-h glucose: −3.7 mmol/L, AUC120: −18.9%) and glibenclamide (−1.0%, −2.2 mmol/L, −2.5 mmol/L, −17.5%). Repaglinide was also associated with an increase in the AUC60 and AUC120 for insulin (+56%, +61%) and C-peptide (+41%, +36%). GLP-1, GIP, IL-6, ICAM-1 and E-selectin levels did not change in either group. No association was observed between GLP-1, GIP-1 and plasma markers of oxidative stress.Repaglinide is associated with improved postprandial glycaemic control via insulin and C-peptide release. We observed no direct effects of glibenclamide or repaglinide on plasma levels of GLP-1 or GIP. We observed no associations of GLP-1 and GIP with plasma markers of oxidative stress.
published_date 2011-12-31T03:12:12Z
_version_ 1763750059624628224
score 11.013686

Similar Items